ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Rohto to start trials for stem cell coronavirus remedy in August

Non-vaccine treatment for ventilator patients due for release after 2021

Rohto Pharmaceutical will test its coronavirus treatment on six patients on ventilators.

OSAKA -- Japan's Rohto Pharmaceutical said Tuesday it plans to launch clinical trials in August for a stem cell-based treatment for patients suffering severe symptoms induced by the novel coronavirus.

The Osaka-based drugmaker looks to verify the safety and effectiveness of the remedy by December 2021 when the tests will close, then quickly put it on the market.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more